| Not Yet Recruiting | Study of CU06-1004 in Patients With Daibetic Macular Edema NCT07459829 | Curacle Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional NCT07457632 | University of Alabama at Birmingham | Phase 2 |
| Enrolling By Invitation | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic So NCT07456826 | Harrow Inc | Phase 4 |
| Not Yet Recruiting | Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monothe NCT07438119 | Kun Liu | Phase 4 |
| Recruiting | Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab NCT07520045 | Osijek University Hospital | N/A |
| Recruiting | Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients NCT07362927 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME NCT07449936 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME NCT07449923 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Not Yet Recruiting | Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery NCT07301775 | Ahmad Zeeshan Jamil | Phase 4 |
| Not Yet Recruiting | Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein NCT06879301 | Tanta University | EARLY_Phase 1 |
| Active Not Recruiting | A Study of Avoralstat In Participants With Diabetic Macular Edema NCT07228559 | BioCryst Pharmaceuticals | Phase 1 |
| Enrolling By Invitation | Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema NCT07338097 | CMH Multan Institute of Medical Sciences | N/A |
| Recruiting | High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy NCT06662994 | Retina Consultants of Orange County | Phase 4 |
| Active Not Recruiting | A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME NCT06957080 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With N NCT06929143 | Bayer | — |
| Recruiting | Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculop NCT06914778 | Hywel Dda Health Board | — |
| Recruiting | Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients NCT06929507 | University Hospital, Alexandroupolis | N/A |
| Completed | A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitrea NCT07484074 | Ollin Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | Study of JMKX003948 Ophthalmic Suspension in Healthy Participants NCT06832657 | Jemincare | Phase 1 |
| Recruiting | A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME NCT06708260 | EnnovaBio | Phase 2 |
| Withdrawn | An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age NCT06398080 | Regeneron Pharmaceuticals | — |
| Active Not Recruiting | A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Followi NCT06664502 | EyeBiotech Ltd. | Phase 1 / Phase 2 |
| Recruiting | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema NCT07515079 | Bio-Thera Solutions | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Partici NCT06571045 | EyeBiotech Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME. NCT06846073 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Completed | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) NCT05989126 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema NCT06116916 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to As NCT05919693 | EyeBiotech Ltd. | Phase 1 / Phase 2 |
| Completed | Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases NCT07514559 | Hospital Hietzing | — |
| Completed | Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Al NCT06882551 | Khyber Teaching Hospital | Phase 4 |
| Completed | Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edem NCT04739306 | Celltrion | Phase 3 |
| Completed | Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD NCT04857996 | Unity Biotechnology, Inc. | Phase 2 |
| Terminated | Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema NCT04697758 | AsclepiX Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular NCT04543331 | Novartis Pharmaceuticals | — |
| Unknown | Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease P NCT03859245 | Bristlecone Health, Inc. | N/A |
| Unknown | The Study to YD312 Tablet in Patients With Diabetic Macular Edema NCT03635814 | YD Global Life Science Co., Ltd. | Phase 2 |
| Completed | Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line NCT02633852 | Hadassah Medical Organization | Phase 4 |
| Completed | Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada NCT02585401 | Bayer | — |
| Completed | Phase 4 IOP Signals Associated With ILUVIEN® NCT02424019 | Alimera Sciences | Phase 4 |
| Completed | The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edem NCT02050828 | Aerpio Therapeutics | Phase 2 |
| Terminated | Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Th NCT02080091 | Alimera Sciences | — |
| Completed | Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema NCT01702441 | Aerpio Therapeutics | Phase 1 / Phase 2 |
| Terminated | SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy NCT00936520 | Johns Hopkins University | Phase 1 |